Salix Pharmaceuticals talks $750 million seven-year notes to yield 6%-6¼%; pricing Thursday

By Paul A. Harris

Portland, Ore., Dec. 11 - Salix Pharmaceuticals Ltd. talked its $750 million offering of seven-year senior notes (B2/B) to yield 6% to 6¼% on Wednesday, according to an informed source.

Books close at 4 p.m. ET Wednesday. However they will remain open until 9 a.m. ET Thursday for accounts meeting with the company Wednesday.

The deal is set to price on Thursday.

Jefferies LLC is the bookrunner for the Rule 144A and Regulation S with registration rights offer.

Fifth Third Securities Inc., Natixis Securities North America Inc., PNC Capital Markets LLC, RBS Securities Inc., SMBC and SunTrust Robinson Humphrey Inc. are the co-managers.

The notes become callable after three years at par plus 75% of the coupon.

Proceeds will be used to help fund the merger with Santarus, Inc.

Salix is a Raleigh, N.C.-based developer and marketer of prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Santarus is a San Diego-based specialty biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.